Citigroup’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.9M | Hold |
20,000
| – | – | 0.01% | 1365 |
|
|
2025
Q4 | $9.74M | Sell |
20,000
-335,000
| -94% | -$156M | ﹤0.01% | 1556 |
|
|
2025
Q3 | $149M | Buy |
355,000
+342,500
| +2,740% | +$115M | 0.07% | 286 |
|
|
2025
Q2 | $3.59M | Buy |
+12,500
| New | +$3.74M | ﹤0.01% | 2161 |
|
|
2024
Q2 | – | Sell |
-309,300
| Closed | -$71.1M | – | 5795 |
|
|
2024
Q1 | $71.1M | Buy |
+309,300
| New | +$69.8M | 0.05% | 359 |
|
|
2021
Q1 | – | Sell |
-1,000
| Closed | -$152K | – | 7439 |
|
|
2020
Q4 | $152K | Sell |
1,000
-3,100
| -76% | -$407K | ﹤0.01% | 5199 |
|
|
2020
Q3 | $414K | Sell |
4,100
-6,900
| -63% | -$757K | ﹤0.01% | 4015 |
|
|
2020
Q2 | $1.33M | Buy |
11,000
+1,300
| +13% | +$146K | ﹤0.01% | 3243 |
|
|
2020
Q1 | $920K | Buy |
9,700
+2,100
| +28% | +$200K | ﹤0.01% | 3265 |
|
|
2019
Q4 | $669K | Sell |
7,600
-14,500
| -66% | -$1.28M | ﹤0.01% | 4160 |
|
|
2019
Q3 | $1.76M | Sell |
22,100
-4,000
| -15% | -$322K | ﹤0.01% | 3012 |
|
|
2019
Q2 | $2.04M | Sell |
26,100
-1,400
| -5% | -$131K | ﹤0.01% | 2827 |
|
|
2019
Q1 | $3.23M | Sell |
27,500
-10,400
| -27% | -$1.21M | ﹤0.01% | 2173 |
|
|
2018
Q4 | $4.13M | Sell |
37,900
-1,200
| -3% | -$139K | ﹤0.01% | 1986 |
|
|
2018
Q3 | $5M | Buy |
39,100
+15,300
| +64% | +$1.89M | ﹤0.01% | 1857 |
|
|
2018
Q2 | $2.69M | Buy |
23,800
+8,900
| +60% | +$978K | ﹤0.01% | 2430 |
|
|
2018
Q1 | $1.67M | Buy |
14,900
+6,000
| +67% | +$762K | ﹤0.01% | 2768 |
|
|
2017
Q4 | $1.32M | Buy |
8,900
+1,300
| +17% | +$165K | ﹤0.01% | 3067 |
|
|
2017
Q3 | $891K | Buy |
7,600
+1,500
| +25% | +$192K | ﹤0.01% | 3504 |
|
|
2017
Q2 | $791K | Hold |
6,100
| – | – | ﹤0.01% | 3553 |
|
|
2017
Q1 | $826K | Sell |
6,100
-20,700
| -77% | -$3.14M | ﹤0.01% | 3417 |
|
|
2016
Q4 | $3.84M | Sell |
26,800
-2,300
| -8% | -$294K | ﹤0.01% | 2133 |
|
|
2016
Q3 | $3.44M | Buy |
29,100
+5,400
| +23% | +$649K | ﹤0.01% | 2019 |
|
|
2016
Q2 | $2.51M | Buy |
23,700
+5,900
| +33% | +$658K | ﹤0.01% | 2167 |
|
|
2016
Q1 | $1.98M | Buy |
17,800
+7,400
| +71% | +$936K | ﹤0.01% | 2498 |
|
|
2015
Q4 | $1.63M | Sell |
10,400
-3,200
| -24% | -$466K | ﹤0.01% | 2644 |
|
|
2015
Q3 | $1.78M | Buy |
13,600
+3,000
| +28% | +$481K | ﹤0.01% | 2553 |
|
|
2015
Q2 | $1.84M | Buy |
+10,600
| New | +$1.91M | ﹤0.01% | 2594 |
|
|
2014
Q2 | – | Sell |
-1,000
| Closed | -$94K | – | 7328 |
|
|
2014
Q1 | $94K | Hold |
1,000
| – | – | ﹤0.01% | 5046 |
|
|
2013
Q4 | $113K | Sell |
1,000
-800
| -44% | -$72.1K | ﹤0.01% | 5158 |
|
|
2013
Q3 | $142K | Sell |
1,800
-16,300
| -90% | -$1.19M | ﹤0.01% | 4442 |
|
|
2013
Q2 | $1.19M | Buy |
+18,100
| New | +$1.17M | ﹤0.01% | 2754 |
|
Other funds holding UTHR
ACA
VPM
VCM
Citigroup's UTHR Position: Q1 2026 in Review
Citigroup increased its United Therapeutics (UTHR) stake by 28% in Q1 2026, buying an estimated $25.5M and bringing the position to 235,620 shares worth $140M. The position accounts for 0.06% of the portfolio, ranked #298.
Citigroup first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. The position peaked at $518M in Q2 2024. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- Citigroup held 235,620 shares of United Therapeutics worth $140M as of Q1 2026.
- Citigroup bought 51,212 United Therapeutics shares in Q1 2026, an estimated $25.5M.
- United Therapeutics made up 0.06% of Citigroup's portfolio in Q1 2026, its #298 holding.
- Citigroup first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Citigroup's United Therapeutics position peaked at $518M in Q2 2024.
- 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.